In Silico Prediction of Human Bioavailability

Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability

Volumn 40, Issue , 2009, Pages 433-451

  Livingstone, David J ^a,b   van de Waterbeemd, Han ^c  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b ChemQuest   (United Kingdom)

^c NONE   (France)

Author keywords

ADMET; Oral bioavailability; PBPK; QSAR; Rule of 5

Indexed keywords

ADMET; ORAL BIOAVAILABILITIES; PBPK; QSAR; RULE-OF-5;

BIOCHEMISTRY;

EID: 77957783737     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623860.ch16     Document Type: Chapter

References (87)

1. Wang, J., Urban, L. and Bojanic, D. (2007) Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opinion on Drug Metabolism and Toxicology, 3, 641-665.
2. Hurst, S., Loi, C.-M., Brodfuehrer, J. and El-Kattan, A. (2007) Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opinion on Drug Metabolism and Toxicology, 3, 469-489.
3. Thomas, V.H., Bhattachar, S., Hitchingham, L., Zocharski, P., Naath, M., Surendran, N., Stoner, C.L. and El-Kattan, A. (2005) The road map to oral bioavailability: an industrial perspective. Expert Opinion on Drug Metabolism and Toxicology, 2, 591-608.
4. Livingstone, D.J. and van de Waterbeemd, H. (2006) In silico models for human bioavailability, in Virtual ADMET Assessment in Target Selection and Maturation (eds B. Testa and L. Turski), IOS Press, Amsterdam, pp. 151-161.
5. Beck-Sickinger, A. and Weber, P. (2002) Combinatorial Strategies in Biology and Chemistry, John Wiley & Sons, Chichester, UK.
6. Dixon, G.K., Major, J.S.andRice, M.J. (eds) (2000) High Throughput Screening The Next Generation, Bios, Oxford, UK.
7. Kennedy, T. (1997) Managing the drug discovery/development interface. Drug Discovery Today, 2, 436-444.
8. Lipper, R.A. (1999) How can we optimize selection of drug development candidates from many compounds at the discovery stage? Modern Drug Discovery, 2, 55-60.
9. Venkatesh, S. and Lipper, R.A. (2000) Role of the development scientist in compound lead selection and optimization. Journal of Pharmaceutical Sciences, 89, 145-154.
10. Forum, General Metrics (2001).
11. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3, 711-715.
12. Bertrand, M., Jackson, P. and Walther, B. (2000) Rapid assessment of drug metabolism in the drug discovery process. European Journal of Pharmaceutical Sciences, 11 (Suppl. 2), S61-S62.
13. Thompson, T.N. (2000) Early ADME in support of drug discovery: the role of metabolic stability studies. Current Drug Metabolism, 1, 215-241.
14. Li, A.P. (2001) Screening for human ADME/Tox drug properties in drug discovery. Drug Discovery Today, 6, 357-366.
15. Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3-25.
16. Bhai, S.K., Kassam, K., Peirson, I.G. and Pearl, G.M. (2007) The rule of five revisited: applying log D in place oflog P in drug-likeness filters. Molecular Pharmacology, 4, 556-560.
17. Hou, T., Wang, J., Zhang, W. and Xu, X. (2007) ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. Journal of Chemical Information and Modeling, 47, 208-218.
18. Martin, Y.C. (2005) Abioavailability score. Journal of Medicinal Chemistry, 48, 3164-3170.
19. Sietsema, W.K. (1989) The absolute oral bioavailability of selected drugs. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 27, 179-211.
20. Mandagere, A.K. and Jones, B. (2003) Prediction of bioavailability, in Drug Bioavailability (eds H. van de Waterbeemd, H. Lennernas and P. Artursson), Wiley VCH Verlag GmbH, Weinheim, pp. 444-460.
21. Grass, G.M. and Sinko, P.J. (2002) Physiologically-based pharmacokinetic simulation modelling. Advanced Drug Delivery Reviews, 54, 433-451.
22. Mandagere, A.K., Thompson, T.N. and Hwang, K.K. (2002) Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. Journal ofMedicinal Chemistry, 45, 30-311.
23. Smith, D.A., van de Waterbeemd, H. and Walker, D.K. (2006) Pharmacokinetics and Metabolism in Drug Design, 2nd edn, Wiley VCH Verlag GmbH, Weinheim.
24. van de Waterbeemd, H., Smith, D.A., Beaumont, K. and Walker, D.K. (2001) Property-based design: optimization of drug absorption and pharmacokinetics. Journal ofMedicinal Chemistry, 44, 1313-1333.
25. vandeWaterbeemd, H. and Rose, S. (2008) Quantitative approaches to quantitative structure-activity relationships, in The Practice ofMedicinal Chemistry, 3rd edn (ed. C.G. Wermuth), Elsevier, Amsterdam.
26. Hirono, S., Nakagome, I., Hirano, H., Matsushita, Y., Yoshi, F. and Moriguchi, I. (1994) Non-congeneric structure pharmacokinetic property correlation studies using fuzzy adaptive least-squares: oral bioavailability. Biological & Pharmaceutical Bulletin, 17, 306-309.
27. Yoshida, F. and Topliss, J.G. (2000) QSAR model for drug human oral bioavailability. Journal of Medicinal Chemistry, 43, 2575-2585.
28. Andrews, C.W., Bennett, L. and Yu, L.X. (2000) Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharmaceutical Research, 17, 639-644.
29. Turner, J.V., Glass, B.D. and Agatonovic Kustrin, S. (2003) Prediction of drug bioavailability based on molecular structure. Analytica Chimica Acta, 485, 89-102.
30. Turner, J.V., Maddalena, D.J. and Agatonovic-Kustrin, S. (2004) Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharmaceutical Research, 21, 68-82.
31. Pintore, M., van de Waterbeemd, H., Piclin, N. and Chretien, J.R. (2003) Prediction of oral bioavailability by adaptive fuzzy partitioning. European Journal ofMedicinal Chemistry, 38, 427-431.
32. Bains, W., Gilbert, R., Sviridenko, L., Gascon, J.L., Scoffin, R., Birchall, K., Harvey, I. and Caldwell, J. (2002) Evolutionary computational methods to predict oral bioavailability QSPRs. Current Opinion in Drug Discovery & Development, 5, 44-51.
33. Wolohan, P.R.N. and Clark, R.D. (2003) Predicting drug pharmacokinetic properties using molecular interaction fields and SIMCA. Journal of Computer Aided Molecular Design, 17, 65-76.
34. Hou, T., Wang, J., Zhang, W. and Xu, X. (2007) ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? Journal of Chemical Information and Modeling, 47, 460-463.
35. Japertas, P., Riauba, L., Zmuidinavicius, D., Didziapetris, R. and Petrauskas, A. (2003) Classification SAR in predicting oral bioavailability, in Designing Drugs and Crop Protectants: Processes, Problems and Solutions (eds M. Ford, D. Livingstone, J. Dearden and H. van de Waterbeemd), Blackwell, Oxford, pp. 229-230.
36. Wang, J., Krudy, G., Xie, X.-Q., Wu, C. and Holland, G. (2006) Genetic algorithm optimized QSPR models for bioavailability, protein binding, and urinary excretion. Journal of Chemical Information and Modeling, 46, 2674-2683.
37. Moda, T.L., Montanari, C.A. and Andricopulo, A.D. (2007) Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic and Medicinal Chemistry, 15, 7738-7745.
38. Turner, J.V. and Agatonovic-Kustrin, S. (2007) In silico prediction of oral bioavailability, in ADME/Tox Approaches, Vol. 5 (eds B. Testa and H. van de Waterbeemd) in Comprehensive Medicinal Chemistry, 2nd edn, Elsevier, Oxford, pp. 699-724.
39. Veber, D.F., Johnson, S.R., Cheng, H.-Y., Smith, B.R., Ward, K.W. and Kopple, K.D. (2002) Molecular properties that influence the oral bioavailability of drug candidates. Journal ofMedicinal Chemistry, 45, 2615-2623.
40. Lu, J.J., Crimin, K., Goodwin, J.T., Crivori, P., Orrenius, C., Xing, L., Tandler, P.J., Vidmar, Th.J., Amore, B.M., Wilson, A.G.E., Stouten, P.F.W. and Burton, P.S. (2004) Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. Journal of Medicinal Chemistry, 47, 610-6107.
41. Clark, R.D. and Wolohan, P.R.N. (2003) Molecular design and bioavailability. Current Topics in Medicinal Chemistry, 3, 1269-1288.
42. Livingstone, D.J. (2003) Theoretical property predictions. Current Topics in Medicinal Chemistry, 3, 1171-1192.
43. Tetko, I.V. and Livingstone, D.J. (2007) Rule-based systems to predict lipophilicity, in ADME/Tox Approaches, Vol. 5 (eds B. Testa and H. van de Waterbeemd), in Comprehensive Medicinal Chemistry, 2nd edn, Elsevier, Oxford, pp. 649-668.
44. Livingstone, D.J., Ford, M.G., Huuskonen, J.J. and Salt, D.W. (2001) Simultaneous prediction of aqueous solubility and octanol/water partition coefficient based on descriptors derived from molecular structure. Journal of Computer-Aided Molecular Design, 15, 741-752.
45. Jorgensen, W.L. and Duffy, E.M. (2002) Prediction of drug solubility from structure. Advanced Drug Delivery Reviews, 54, 355-366.
46. Manallack, D.T., Tehan, B.G., Gancia, E., Hudson, B.D., Ford, M.G., Livingstone, D.J., Whitley, D.C. and Pitt, W.R. (2003) A consensus neural network-based technique for discriminating soluble and insoluble compounds. Journal ofChemical Information and Computer Sciences, 43, 67-679.
47. Morris, J.J. and Bruneau, P.P. (2000) Prediction of physicochemical properties, in Virtual Screening for Bioactive Molecules (eds H.J. Bohm and G. Schneider), John Wiley & Sons, Ltd, Chichester, pp. 33-58.
48. Egan, W.J. and Lauri, G. (2002) Prediction of intestinal permeability. Advanced Drug Delivery Reviews, 54, 273-289.
49. Kulkarni, A., Yi, H. and Hopfinger, A.J. (2002) Predicting Caco-2 cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis. Journal of Chemical Information and Computer Sciences, 42, 331-342.
50. van de Waterbeemd, H. and Gifford, E. (2003) ADMET in silico modelling: towards prediction paradise? Nature Reviews Drug Discovery, 2, 192-204.
51. van de Waterbeemd, H. (2007) In silico models to predict oral absorption, in ADME/ToxApproaches, Vol. 5 (eds B. Testa and H. van de Waterbeemd), in Comprehensive Medicinal Chemistry, 2nd edn, Elsevier, Oxford, pp. 669-698.
52. Kratochwil, N.A., Huber, W., Muller, F., Kansy, M. and Gerber, P.R. (2002) Predicting plasma protein binding of drugs: a new approach. Biochemical Pharmacology, 64, 1355-1374.
53. Stouch, T.R. and Gudmundsson, O. (2002) Progress in understanding the structure-activity relationships of P lycoprotein. Advanced Drug Delivery Reviews, 54, 315-328.
54. Zhang, E.Y., Phelps, M.A., Cheng, C., Ekins, S. and Swaan, P.W. (2002) Modeling of active transport systems. Advanced Drug Delivery Reviews, 54, 329-354.
55. Jones, J.P., Mysinger, M. and Korzekwa, K.R. (2002) Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 30, 7-12.
56. Arimoto, R. (2006) Computational models for predicting interactions with cytochrome P 450 enzyme. Current Topics in Medicinal Chemistry, 6, 1609-1618.
57. Boobis, A., Gundert-Remy, U., Kremers, P., Macheras, P. and Pelkonen, O. (2002) In silico prediction ofADME and pharmacokinetics. Report of an expert meeting organized by COST B15. European Journal of Pharmaceutical Sciences, 17, 183-193.
58. Terfloth, L., Bienfait, B. and Gasteiger, J. (2007) Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. Journal of Chemical Information and Modeling, 47, 1688-1701.
59. Sheridan, R.P., Korzekwa, K.R., Torres, R.A. and Walker, M.J. (2007) Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. Journal ofMedicinal Chemistry, 50, 3173-3184.
60. Afzelius, L., Hasselgren Arnby, C., Broo, A., Carlsson, L., Isaksson, C., Jurva, U., Kjellander, B., Kolmodin, K., Nilsson, K., Raubacher, F. and Weidolf, L. (2007) State of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications. Drug Metabolism Reviews, 39, 61-86.
61. Ekins, S., Nikolsky, Y. and Nikolskaya, T. (2005) Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends in Pharmacological Sciences, 26, 202-209.
62. Greene, N., Judson, P.N., Langowski, J.J. and Marchant, C.A. (1999) Knowledge based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR and QSAR in Environmental Research, 10, 299-314.
63. Testa, B., Balmat, A.L., Long, A. and Judson, P. (2005) Predicting drug metabolism? An evaluation of the expert system METEOR. Chemistry & Biodiversity, 2, 872-885.
64. Crivori, P., Zamora, I., Speed, B., Orrenius, C. and Poggesi, I. (2004) Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates. Journal of Computer-Aided Molecular Design, 18, 155-166.
65. Ekins, S., de Groot, M.J. and Jones, J.P. (2001) Pharmacophore and three dimensional quantitative structure activity relationship methods for modelling cytochrome P450 active sites. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 29, 936-944.
66. Crivori, P. and Poggesi, I. (2006) Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. European Journal of Medicinal Chemistry, 41, 795-808.
67. Kuhn, B., Jacobsen, W., Christians, U., Benet, L.Z. and Kollman, P.A. (2001) Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics and quantum chemical calculations. Journal ofMedicinal Chemistry, 44, 2027-2034.
68. Afzelius, L., Raubacher, F., Karlen, A., Jorgensen, F.S., Andersson, T.B., Masimirembwa, C. and Zamora, I. (2004) Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modelling techniques. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 32, 1-12.
69. Boyer, S. and Zamora, I. (2002) New methods in predictive metabolism. Journal ofComputer-Aided Molecular Design, 16, 403-413.
70. van de Waterbeemd, H. and Jones, B.C. (2003) Predicting oral absorption and bioavailability. Progress in Medicinal Chemistry, 41, 1-59.
71. Stouch, T.R., Kenyon, J.R., Johnson, S.R., Chen, X.-Q., Doweyko, A. and Li, Y. (2003) In silico ADME/Tox: why models fail. Journal ofComputer-Aided Molecular Design, 17, 83-92.
72. Yamashita, F. and Hashida, M. (2004) In silico approaches for predicting ADME properties of drugs. Drug Metabolism and Pharmacokinetics, 19, 327-338.
73. Mager, D.E. (2006) Quantitative structure-pharmacokinetic/ pharmacodynamic relationships. Advanced Drug Delivery Reviews, 58, 1326-1356.
74. De Buck, S.S., Sinha, V.K., Fenu, L.A., Nijsen, M.J., Mackie, C.E. and Gilissen, R.A.H.J. (2007) Prediction of human pharmacokinetics using physiologically based modelling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35, 1766-1780.
75. Theil, F.-P., Guentert, T.W., Haddad, S. and Poulin, P. (2003) Utility of physiologically-based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicology Letters, 138, 29-39.
76. Dickins, M. and van de Waterbeemd, H. (2004) Simulation models for drug disposition and drug interactions. Drug Discovery Today: Biosilico, 2, 38-45.
77. Germani, M., Crivori, P., Rocchetti, M., Burton, P.S., Wilson, A.G.E., Smith, M.E. and Poggesi, I. (2007) Evaluation of a basic physiologically-based pharmacokinetic model for simulating the first-time-in-animal study. European Journal of Pharmaceutical Sciences, 31, 190-201.
78. Andersen, M.E. (1995) Physiologically based pharmacokinetic (PBPK) models in the study of the disposition and biological effects of xenobiotics and drugs. Toxicology Letters, 82/83, 341-348.
79. Kuentz, M., Nick, S., Parrott, N. and Rothlisberger, D. (2006) A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. European Journal of Pharmaceutical Sciences, 27, 91-99.
80. Kawai, R., Lemaire, M., Steimer, J.-L., Bruelisauer, A., Niederberger, W. and Rowland, M. (1994) Physiologically-based pharmacokinetic study on a cyclosporine derivative, SDZ IMM 125. Journal of Pharmacokinetics and Biopharmaceutics, 22, 327-365.
81. Charnik, S.B., Kawai, R., Nefelman, J.R., Lemaire, M., Niederberger, W. and Sato, H. (1995) Perspectives in pharmacokinetics. Physiologically-based pharmacokinetic modeling as a tool for drug development. Journal ofPharmacokinetics and Biopharmaceutics, 23, 231-235.
82. Leahy, D.E. (2003) Progress in simulation modelling for pharmacokinetics. Current Topics in Medicinal Chemistry, 3,1257-1268.
83. Stoner, C.L., Cleton, A., Johnson, K., Oh, D.-M., Hallak, H. Brodfuehrer, Surendran, N. and Han, H.-K. (2004) Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. International Journal of Pharmaceutics, 269, 241-249.
84. Cai, H., Stoner, C., Reddy, A., Freiwald, S., Smith, D., Winters, R., Stankovic, C. and Surendran, N. (2006) Evaluation of an integrated in vitro in silico PBPK (physiologically-based pharmacokinetic) model to provide estimates of human bioavailability. International Journal of Pharmaceutics, 308, 133-139.
85. Verwei, M., Freidig, A.P., Havenaar, R. and Groten, J.P. (2006) Predicted serum folate concentrations based on in vitro studies and kinetic modelling are consistent with measured folate concentrations in humans. The Journal ofNutrition, 136, 3074-3078.
86. Leeson, P.D. and Springthorpe, B. (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Reviews Drug Discovery, 6, 881-890.
87. Gu, C.H., Li, H., Levons, J., Leatz, K., Gandhi, R.B., Raghavan, K. and Smith, R.L. (2007) Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharmaceutical Research, 24, 1118-1130.